Signaling pathways activated by daunorubicin.
The anthracycline daunorubicin is widely used in the treatment of acute nonlymphocytic leukemia. The drug has, of course, been the object of intense basic research, as well as preclinical and clinical study. As reviewed in this article, evidence stemming from this research clearly demonstrates that cell response to daunorubicin is highly regulated by multiple signaling events, including a sphingomyelinase-initiated sphingomyelin-ceramide pathway, mitogen-activated kinase and stress-activated protein/c-Jun N-terminal kinase activation, transcription factors such as nuclear factor kappa B, as well as the Fas/Fas-ligand system. These pathways are themselves influenced by a number of lipid products (diacylglycerol, sphingosine-1 phosphate, and glucosyl ceramide), reactive oxygen species, oncogenes (such as the tumor suppressor gene p53), protein kinases (protein kinase C and phosphoinositide-3 kinase), and external stimuli (hematopoietic growth factors and the extracellular matrix). In light of the complexity and diversity of these observations, a comprehensive review has been attempted toward the understanding of their individual implication (and regulation) in daunorubicin-induced signaling. (Blood. 2001;98:913-924)
Laurent
G
G
INSERM E9910, Institut Claudius Régaud, Toulouse, France. laurent@icr.fnclcc.fr
Jaffrézou
J P
JP
D000903:Antibiotics, Antineoplastic / Q000494:pharmacology; D003630:Daunorubicin / Q000494:pharmacology*; D006801:Humans; D015398:Signal Transduction / Q000187:drug effects*
D000903:Antibiotics, Antineoplastic; D003630:Daunorubicin